NeoGenomics' stock price dropped by 15.50% due to missing revenue estimates, despite showing revenue growth and increasing clinical volume. The company's negative net income and free cash flow contribute to its overvaluation, leading to a Hold rating. While there is long-term growth potential due to rising cancer cases and improving ROIC, the current negative profitability is a significant concern for investors.